ABSTRACT
INTRODUCTION
Hyperthermia seems to be an effective synergistic anticancer treatment, in conjunction or not with radiotherapy, chemotherapy and surgery. This method is based on the increase of tumour temperature up to 40°C -45°C by electromagnetic energy (1) (2) (3) . Superficial hyperthermia is used for tumours that are at a depth less than 5 cm from the skin surface, such as breast cancer (BC), head and neck (HN) cancer or melanoma (4) . Although there is great knowledge about BC, it still represents a major health problem, as there is an increasing number of cases that are reported yearly (5) (6) (7) . On the other hand, despite the efficacy of the multimodal treatment -surgery, radiotherapy, chemotherapy and molecular targeted therapies -more than 50% of patients suffering from HN cancer will relapse or will have a metastatic disease (8) . Hyperthermia definitely has a synergistic effect with irradiation for superficial tumours related to breast or head and neck cancers (9) .
The aim of the study was to assess the correlation (primary endpoint) of thermal parameters of hyperthermia to both clinical outcome and tumour regression. The secondary endpoint was to evaluate the efficacy of hyperthermia to superficial tumours when added to radiotherapy.
SUBJECTS AND METHODS
In this study, 20 patients were included with superficial tumours whose depth was less than 5 cm from skin surface. These patients received radiotherapy in conjunction with hyperthermia (RTHT). The patients' characteristics are presented in Table 1 . The patients that were enrolled in the study were suffering from submandibular lymph nodes related to HN cancer, or post-mastectomy relapses on the anterior front chest wall from BC. Before the beginning of the therapy, the patients received a computed tomography (CT) scan and the tumour diameter was measured. All patients received RTHT.
According to the study protocol, the patients that were enrolled met the following criteria:
* Histologically proven superficial cancer at depth less than 5 cm from skin surface. * Contrast-enhanced CT scan performed before treatment. * Normal electrocardiogram and normal chest wall Xray. * Age 18-80 years old and life expectancy greater than two months. * Karnofsky performance status > 70% and World Health Organization (WHO) status 0-1. * Laboratory values (performed one week before study): absolute neutrophil count > 3000/mm 3 , platelet count > 100.000/mm 3 , haemoglobin > 10 g/dL. * Urea and serum creatinine lower than upper limit of laboratory normal. * Total and direct bilirubin lower than upper limit of laboratory normal. * Serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase lower than upper limit of laboratory normal. * Alkaline phosphatase lower than upper limit of laboratory normal. The exclusion criteria for the study were: * Age > 80 years old * WHO status > 1 * Patients with pacemaker and implanted electronic devices * Patients with implanted stents * Patients with fever before treatment This study was conducted in accordance with the Declaration of Helsinki and all patients gave written informed consent which included the treatment and the related potential toxicity.
Radiotherapy
All patients received contrast-enhanced CT before treatment, for the location of the tumour and the determination of its diameter. This CT was used for the treatment planning of We used linear-quadratic (LQ) modelling in order to equate the hypofractionation schedule to the normalized total dose (NTD) if delivered in 2 Gy fractions (10). Thus, NTD represents the dose given in 2 Gy fractions that would give the equivalent biologic effect to the new hypofractionated dose:
where D new and d new are, respectively the total dose and dose per fraction for a suggested hypofractionation scheme. Normalized total dose has been calculated and tabulated for late reacting tissues with α/β = 3 Gy (11). According to the previous calculations, the equivalent dose NTD varied from 54-60 Gy.
Hyperthermia
The hyperthermia session lasted one hour and was realized within one hour after radiotherapy. During hyperthermia, the intention was to reach the tumour temperature between 42°C and 45°C. The heating was superficial and was realized by waveguided applicators of circular or rectangular shape opernot exceed the therapeutic range. These data were not recorded; they were only monitored for safety reasons. The second thermocouple was inserted interstitially into the tumour after a local anaesthetic (Fig. 3) . This thermocouple ating at the frequency of 433 MHz (Figs. 1, 2 ). These applicators were constructed in the National Technical University of Athens. They were water cooled for the skin surface in order to avoid thermal blistering and burns which might occur on the skin from the electromagnetic power (12) . During the hyperthermia session, two thermocouples were used for recording the temperature. The first one was placed on the skin surface, near the applicator, during the whole session to ensure that the skin surface temperature did had three points of measurement along its axis and counted the tumour temperature at depths 1, 1.8, and 2.6 cm during the whole hyperthermia session. These data were stored in a computer using a compatible data acquisition system (13). The patients underwent one or more weekly hyperthermia sessions, depending on the irradiation schedule (one or four weeks).
Treatment evaluation
Two or three months after the completion of the therapy, each patient was subjected to another CT scan for the determination of the tumour reduction and the potential tumour response to the therapy.
It was considered: * Complete response (CR): 100% tumour regression * Partial response (PR): ≥ 50% tumour regression * Stable disease (SD): < 25% tumour regression * Progressive disease (PD): ≥ 25% increase in tumour volume
Statistical analysis
These tumour temperature data were entered onto a worksheet for further analysis. The thermal parameters that were calculated were: * Tmin: the minimum tumour temperature during hyperthermia -average minimum for the three depths * Tmax: the maximum tumour temperature during hyperthermia -average maximum for the three depths * Time (T 90 > 44°C): time in minutes during which 90% of the recorded temperatures exceeded 44°C -average for the three depths. Finally, the correlation was assessed with Spearman rho correlation coefficient between the above-calculated thermal parameters and the decrease of the maximum tumour diameter. The significance level was set at 0.05. The whole analysis was performed with SPSS version 10 (Chicago, IL, USA).
RESULTS
During the hyperthermia session, the tumour temperature data were recorded and were further analysed in order to calculate the minimum tumour temperature (Tmin), the maximum tumour temperature (Tmax) and Time [T 90 > 44°C
]. As the thermocouple was recording the temperature for three different depths, the average for these parameters was calculated. The mean, standard deviation, median and range of Tmin, Tmax, Time [T 90 > 44°C], irradiation dose and tumour diameter decrease are shown in Table 2 . Among the DISCUSSION Many trials have already shown that RTHT for the treatment of superficial tumours is promising in its clinical outcome. In clinical oncology, superficial hyperthermia is mainly used for the treatment of breast cancer, head and neck cancer and melanoma. In most cases where patients received RTHT, it is shown that they responded positively to the treatment (14) (15) (16) . In addition, it has been observed that patients who are treated with RTHT have a greater complete response rate than those who are treated with irradiation alone. One of the greatest collections of data was realized by the collaboration of five different institutes -hospitals: it was found that the complete response rates were 59% and 41% with or without hyperthermia, respectively, while for patients that were previously irradiated the rates were 57% and 31%, respectively (1, 17). Perez et al observed that hyperthermia helps the treatment of superficial tumours, especially of those with diameters < 3 cm. They noticed that the complete response rates were increased from 40% to 62% for breast cancers, from 0% to 67% for trunk and extremities and from 38% to 50% for head and neck cancers (18) . Gabriele et al (19) showed that for the patients with breast cancer -45 days after the completion of the therapy -the complete response rates were 65.9% and the partial response rates were 29.5%. For patients with melanoma, the rates were 33.3% and 25%, respectively; for patients with head and neck cancer, 40% and 13.3%, respectively and for patients suffering from other kinds of superficial tumours the complete response rate was No correlation was found neither between the minimum nor the maximum tumour temperature and the therapeutic outcome (Spearman rho = -0.0037, p = 0.46 and rho = -0.0052, p = 0.27, respectively). Moreover, no correlation was noted between decrease of tumour dimensions and irradiation dose (Spearman rho = 0.04, p = 0.18). However, as shown in Fig. 4 , a statistically significant correlation was noted between Time [T 90 > 44°C] and the tumour reduction after the completion of the therapy (Spearman rho = 0.42, p < 0.001). Thermal Parameters and Tumour Response 60% and the non-response rate was 40%. Overgaard et al (20) showed that 62% of melanoma lesions responded completely after the RTHT. As for breast cancer, the complete response rates that have been reported are 77.7%, 71% and 74% (21) (22) (23) . For head and neck cancer, the complete response rates that are reported are 55% versus 31% for the patients that received only radiotherapy (24) . In our study, the patients that were enrolled had superficial lesions and were treated with RTHT. It is important to mention that after the end of treatment, a reduction of the diameter was observed in all tumours and 75% of patients responded completely to RTHT, which is in accordance with the current literature.
The main aim of our study was to test the correlation between the thermal parameters of hyperthermia and the reduction of the tumour diameter after the completion of the therapy. Trials like those of Cox and Kapp (25, 26) have shown that between other thermal parameters (thermal dose -T 90 ), the minimum tumour temperature correlates with the patients' response. Similar results were also reported from Kouloulias et al in a previous study of application of superficial hyperthermia in Greece (12) . The minimum temperature has also been found to correlate with local control (1). However, in our trial, minimum temperature was not proven to be an important parameter for the clinical outcome. The same results were shown for the maximum tumour temperature. These contradictive results probably might be explained from the small number of patients.
The only thermal parameter that seems to correlate with the tumour regression is the Time [T 90 > 44°C] (p < 0.001). Similar results have been shown by Hand et al (27) as they proved that the time during which the temperature was greater than 42°C correlates with complete response. In addition, Kouloulias et al (13) , testing the application of hyperthermia in anterior chest wall recurrences from breast cancer, showed that there was a statistically significant correlation between Time [T 90 > 44°C] and the disease-free interval to local relapse.
Hyperthermia has the advantage of being a painless therapeutic modality. The most common toxicity is thermal blistering, thermal burns and in some occasions, enhancement of acute reactions of radiation. It is more rarely reported that the interstitial placement of the thermocouple might cause pain and infections (28) (29) (30) (31) . All these reactions can be easily cured with medication. In our study, none of the patients reported pain or any reaction, except from a mild erythema.
The present study should be considered as a preliminary report. This work is ongoing since hyperthermia has been included in the routine clinical practice of our radiotherapy departments. In conclusion, it is considered necessary that more patients should be included in future clinical trials for further confirmation of the parameters that result in the optimization of the clinical application of the method. Efforts in hyperthermia must be made in order to retain the temperature inside the tumour above 44°C for as long as possible.
